Losartan in Situ Forming Gel as a New Treatment for Hypertrophic Scars.
Healing
Hypertrophic scars
Losartan in situ forming gel
Triamcinolone
Wound
Journal
Aesthetic plastic surgery
ISSN: 1432-5241
Titre abrégé: Aesthetic Plast Surg
Pays: United States
ID NLM: 7701756
Informations de publication
Date de publication:
25 Sep 2024
25 Sep 2024
Historique:
received:
29
06
2024
accepted:
03
09
2024
medline:
25
9
2024
pubmed:
25
9
2024
entrez:
24
9
2024
Statut:
aheadofprint
Résumé
Hypertrophic scars are defined as visible lesions formed by excessive wound healing that cause cosmetic and, in some cases, functional challenges in patients. This study aimed to assess the efficacy of intralesional injections of losartan-loaded in situ forming gel and compare it with the common treatment (triamcinolone) in preventing scar formation. The formulation was prepared using a thermosensitive PLGA-PEG-PLGA triblock copolymer. Ear scar tissue in rabbits represented the hypertrophic scar, and the animals were treated with three treatments in three groups. Nine weeks following the single treatment, images of the scars were obtained and quantitatively analyzed using ImageJ and light microscopy was used to evaluate the fibroblast cell number, vascularization, inflammation and collagen deposition and fibrosis in H&E-stained sample tissue. According to the results based on the ImageJ and the Vancouver criteria, the losartan in situ forming gel (F-LG) indicated significantly higher improving effects on decreased vascularity and pigmentation in comparison with triamcinolone (F-TA) and placebo as a control (F-Ctl), although the effect F-LG was almost similar to F-TA on pliability and scar height, and they were better than the control. Histological findings showed F-LG and F-TA have less inflammatory and fibroblast cells compared to F-Ctl. Also, results indicated the dermal layers of the F-TA and F-LG groups' scar were thinner, and the deposition of collagens was reduced compared to the control. Consequently, F-LG was found to be an effective treatment in reducing scarring and promoting wound healing.No Level Assigned This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Identifiants
pubmed: 39317863
doi: 10.1007/s00266-024-04385-4
pii: 10.1007/s00266-024-04385-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Springer Science+Business Media, LLC, part of Springer Nature and International Society of Aesthetic Plastic Surgery.
Références
Ashraf SS et al (2023) Regenerative medicine improve neurodegenerative diseases. Cell Tissue Bank 24(3):639–650
doi: 10.1007/s10561-022-10062-0
pubmed: 36527565
Mony MP et al (2023) An updated review of hypertrophic scarring. Cells 12(5):678
doi: 10.3390/cells12050678
pubmed: 36899815
pmcid: 10000648
Frech FS et al (2023) Hypertrophic scars and keloids: advances in treatment and review of established therapies. Am J Clin Dermatol 1–21
Oosterhoff TC et al (2021) Laser treatment of specific scar characteristics in hypertrophic scars and keloid: a systematic review. J Plast Reconstr Aesthet Surg 74(1):48–64
doi: 10.1016/j.bjps.2020.08.108
pubmed: 33645505
Waibel JS, Wulkan AJ, Shumaker PR (2013) Treatment of hypertrophic scars using laser and laser assisted corticosteroid delivery. Lasers Surg Med 45(3):135–140
doi: 10.1002/lsm.22120
pubmed: 23460557
O’Boyle CP, Shayan-Arani H, Hamada MW (2017) Intralesional cryotherapy for hypertrophic scars and keloids: a review. Scars, Burns Healing 3:2059513117702162
doi: 10.1177/2059513117702162
pubmed: 29799581
pmcid: 5965337
Ahn ST, Monafo WW, Mustoe TA (1989) Topical silicone gel: a new treatment for hypertrophic scars. Surgery 106(4):781–787
pubmed: 2529659
Mutalik S (2005) Treatment of keloids and hypertrophic scars. Indian J Dermatol Venereol Leprol 71:3
doi: 10.4103/0378-6323.13777
pubmed: 16394352
Juckett G, Hartman-Adams H (2009) Management of keloids and hypertrophic scars. Am Fam Physician 80(3):253–260
pubmed: 19621835
Nischwitz SP et al (2023) The role of local inflammation and hypoxia in the formation of hypertrophic scars—a new model in the duroc pig. Int J Mol Sci 24(1):316
doi: 10.3390/ijms24010316
Huang Y et al (2023) Intradermal delivery of an angiotensin II receptor blocker using a personalized microneedle patch for treatment of hypertrophic scars. Biomater Sci 11:583
doi: 10.1039/D2BM01631A
pubmed: 36475528
Hedayatyanfard K et al (2020) The renin-angiotensin system in cutaneous hypertrophic scar and keloid formation. Exp Dermatol 29(9):902–909
doi: 10.1111/exd.14154
pubmed: 32678966
Niazi F et al (2018) Detection of angiotensin II and AT1 receptor concentrations in keloid and hypertrophic scar. J Clin Aesthet Dermatol 11(10):36
pubmed: 30519378
pmcid: 6239163
Liu H-W et al (2006) Angiotensin II regulates phosphoinositide 3 kinase/Akt cascade via a negative crosstalk between AT1 and AT2 receptors in skin fibroblasts of human hypertrophic scars. Life Sci 79(5):475–483
doi: 10.1016/j.lfs.2006.01.031
pubmed: 16522324
Tan WQ et al (2018) Angiotensin-converting enzyme inhibitor works as a scar formation inhibitor by down-regulating Smad and TGF-β-activated kinase 1 (TAK1) pathways in mice. Br J Pharmacol 175(22):4239–4252
doi: 10.1111/bph.14489
pubmed: 30153328
pmcid: 6193878
Zhang T et al (2020) Current potential therapeutic strategies targeting the TGF-β/Smad signaling pathway to attenuate keloid and hypertrophic scar formation. Biomed Pharmacother 129:110287
doi: 10.1016/j.biopha.2020.110287
pubmed: 32540643
Zentner GM et al (2001) Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Controll Release 72(1–3):203–215
doi: 10.1016/S0168-3659(01)00276-0
Bennison LR et al (2017) The pH of wounds during healing and infection: A descriptive literature review. Wound Pract Res: J Australian Wound Manag Assoc 25:63
Zhang Y et al (2010) DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J 12:263–271
doi: 10.1208/s12248-010-9185-1
pubmed: 20373062
pmcid: 2895453
Li J et al (2020) Experimental models for cutaneous hypertrophic scar research. Wound Repair Regen 28(1):126–144
doi: 10.1111/wrr.12760
pubmed: 31509318
Gharahgheshlagh SN et al (2024) Fabricating modified cotton wound dressing via exopolysaccharide-incorporated marine collagen nanofibers. Mater Today Commun 39:108706
doi: 10.1016/j.mtcomm.2024.108706
Huang T-Y et al (2021) Scar-reducing effects of gambogenic acid on skin wounds in rabbit ears. Int Immunopharmacol 90:107200
doi: 10.1016/j.intimp.2020.107200
pubmed: 33246825
Hivechi A et al (2023) Oxidized carboxymethyl cellulose/gelatin in situ gelling hydrogel for accelerated diabetic wound healing: synthesis, characterization, and in vivo investigations. Int J Biol Macromol 242:125127
doi: 10.1016/j.ijbiomac.2023.125127
pubmed: 37263327
Ghadimi T et al (2023) The effect of rainbow trout (Onchorhynchus mykiss) collagen Incorporated with exopolysaccharides derived from Rhodotorula mucilaginosa sp. on burn healing. Macromol Biosci 23:2300033
doi: 10.1002/mabi.202300033
Naderi Gharehgheshlagh S et al (2021) A dermal gel made of Rutilus kutum skin collagen-chitosan for deep burn healing. Int J Pept Res Ther 27:317–328
doi: 10.1007/s10989-020-10082-y
Kant S et al (2018) A new treatment of hypertrophic and keloid scars with combined triamcinolone and verapamil: a retrospective study. Eur J Plast Surg 41:69–80
doi: 10.1007/s00238-017-1322-y
pubmed: 29398785
Morelli Coppola M et al (2018) Triamcinolone acetonide intralesional injection for the treatment of keloid scars: patient selection and perspectives. Clin Cosmet Investig Dermatol 11:387–396
doi: 10.2147/CCID.S133672
pubmed: 30087573
pmcid: 6063260
Marshall CD et al (2018) Cutaneous scarring: basic science, current treatments, and future directions. Adv Wound Care 7(2):29–45
doi: 10.1089/wound.2016.0696
Hedayatyanfard K et al (2018) Losartan ointment relieves hypertrophic scars and keloid: a pilot study. Wound Repair Regen 26(4):340–343
doi: 10.1111/wrr.12648
pubmed: 30099811
Dow T, Selman T, Williams J, Bezuhly M (2023) The role of ACE-Inhibitors and ARBs in reducing hypertrophic scarring following bilateral breast reduction. J Plast Reconstr Aesthet Surg 78:1–3
doi: 10.1016/j.bjps.2022.11.032
pubmed: 36669236
Hu Y-Y, Fang Q-Q, Wang X-F et al (2020) Angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor blocker: potential agents to reduce post-surgical scar formation in humans. Basic Clin Pharmacol Toxicol 127:488–494
doi: 10.1111/bcpt.13458
pubmed: 32564469
Zhao W-Y et al (2022) The compound losartan cream inhibits scar formation via TGF-β/Smad pathway. Sci Rep 12(1):14327
doi: 10.1038/s41598-022-17686-y
pubmed: 35995975
pmcid: 9395380
Zheng Bin, Fang Qing-Qing, Wang Xiao-Feng, Shi Bang-Hui, Zhao Wan-Yi, Chen Chun-Ye, Zhang Min-Xia, Zhang Li-Yun, Yan-Yan Hu, Shi Peng, Ma Lie, Tan Wei-Qiang (2019) The effect of topical ramipril and losartan cream in inhibiting scar formation. Biomed Pharmacother 118:109394
doi: 10.1016/j.biopha.2019.109394
pubmed: 31545259
Demir CY et al (2018) Comparison of enalapril, candesartan and intralesional triamcinolone in reducing hypertrophic scar development: An experimental study. Aesthetic Plast Surg 42:352–361
doi: 10.1007/s00266-018-1073-6
pubmed: 29349667